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Summary
TheT cell receptor repertoire has a potential for vast diversity. However, this diversity is limited
by the fact that the majority of thymocytes die as the repertoire is shaped by positive and negative
selection events during development . Such thymic selection affecting TCR VO gene segment
usage has been demonstrated in the mouse . However, similar data has not been forthcoming
in man, and little isknown about the role of theTCRa chain in antigen/major histocompatibility
complex (MHC) recognition in any species. Here, we used a monoclonal antibody recognizing
the TCR Va12.1 gene product to assess the expression of this gene in the peripheral blood of
man. In most individuals tested, the percentage of cells expressingVa12.1 was significantly higher
in CD8+ T cells than in CD4+ T cells. That the Va gene product itself was responsible for
this increased expression in CD8+ T cells was underscored by the lack of substantial skewing
of V/3 usage in the Va12.1-bearing T cells . Moreover, the skewed expression of Va111 was
already present at birth, indicating that it was likely to be due to a developmental process rather
than the result of exposure to environmental antigens. Based on the established role for CD8
in binding to class IMHC molecules, we suggest that increased expression of Va112.1 on CD8+
T cells points to a role for TCR's using Va12.1 in class I MHC/Ag recognition. These results
indicate that Va gene usage in the peripheral blood ofman is not random, and they support
a role for Va as a participant in the self-MHC recognition process that shapes the TCRrepertoire .
T
cells play a central role in immunity through specific
recognition of foreign peptides bound to self-MHC mol-
ecules . This recognition of antigen and self-MHC is carried
out by clonotypic a(d T cell receptors, present on the surface
ofT lymphocytes in association with theCD3 complex (1) .
TCR a and /3 chains are assembled by somatic recombina-
tion of discontinuous germline gene segments duringT cell
development . The generation of a diverse repertoire ofhuman
as TCRs is accomplished by the recombination of a single
V gene segment (selected from a pool of approximately 100
Vas and 80 Vos) to an individual J gene segment (out of
approximately 100 Jas and 13 JOs) . Template-independent
nucleotide (N-segment) insertions at thejunctions, Do usage,
and the imprecisejoining of the germline gene segments fur-
ther increase TCR diversity (2, 3) . However, in a given in-
dividual the potentially large repertoire of TCR structures
may not actually be used by mature peripheral T cells . For
instance, thymocytes bearingTCRs strongly autoreactive to
self-MHC molecules are clonally deleted (negative selection)
to achieve self-tolerance during thymic maturation (4, 5) . In
addition, lymphocytes bearing transgenic TCRs restricted to
a particularMHC allele fail to develop fully in mice lacking
the appropriate MHC molecule. These and other data led
to the suggestion that a process ofpositive selection may also
shape the peripheral TCR repertoire in mice and relate to
the self-MHC restricted recognition of antigens by periph-
eral T lymphocytes (6-8) . With few exceptions, mature aO
bearing T lymphocytes in the periphery are either CD8+
and restricted to class I MHC molecules, or are CD4+ and
restricted to class II MHC molecules (9) .
Molecular modeling predicts that theV gene segment en-
codedCDR 1 and 2 may contact theMHC molecule, while
the V(D(3)J junctional sequence encoded CDR3 may be
oriented to interact predominantly with the foreign antigen
peptide (3, 10) . However, most studies to date supporting
the role ofTCR segments in determining the fate ofT cells
during the process of thymic selection and in their subse-
quent function in cell-mediated immune responses are based
largely on analyses ofVO gene products (11, 12) . In contrast,
little correlation between the expression of particular TCR
a chains andMHC recognition or thymic selection has been
reported. The few studies available to date implicate theTCR
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dence has shown a role in MHC recognition .
Here, aVcd11-specificmAb enabled us to analyze the ex-
pression of this gene segmentin peripheral bloodTcell subsets
by flow cytometry. Most individuals expressed the Va12.1
gene segmentwith significantlyhigher frequency (up to three-
fold) on CD8+ T cells in comparison with CD4' T cells .
This phenomenon is likely to be mediated by a process acting
on theVa12.1 gene product itself, since theconcomitant usage
of Vii genes was heterogenous and similar in both CD4+
and CD8+ subsets of T cells . Moreover, the biased expres-
sion of Va1I1 on CD8+ T cells was present at birth, be-
fore antigenic challenge, suggesting that it maybe the result
of thymic selection events and not of foreign antigen-driven
peripheral expansion .
Materials and Methods
Antibodies.
￿
ThemAb6136 wasgeneratedby injectingBALB/c
mice at monthly intervals with TCR ag complexes isolated from
the humanTleukemia cell line HPB-MLTTCRcomplexes were
partially purified by immunoprecipitation using anti-CD3 mAb
adsorbed to Protein A bearing fixed Staphylococcus aureus bacteria
(Pansorbin; Calbiochem Corp., San Diego, CA) using a protocol
described previously (13) . Immune spleen cells were fused with
P3X63Ag8.653 myeloma cells in the presence ofpolyethylene glycol
1500 (British Drug House, Carlplace, NY). The fused cells were
then selected in the presence of hypoxanthine-aminopterin-
thymidine (Sigma Chemical Co., St . Louis, MO) at 101/well in
96-well plates . Supernatants from wells positive for growth were
screened by immunoprecipitation on 1151-labeled HPB-MLT cell ly-
sates. One of the hybridomas that produced antibodies that
specifically immunoprecipitated HPB-MLT TCRcomplex was
selected andsubdoned for additional study. Thehybridoma product,
mAb6136, was identified as IgG1 by immunodiffusion analysis and
is specific for Va111 encoded products (see Text) .
MAb 3A2was also generated against the HPB-MLTTCRag-
complex using the same protocol . It was shown to be specific for
theS chain ofHPB-MLT(V#5.3)by immunoprecipitation experi-
ments (see Fig. 2 B, lane 3) . In addition to immunofluorescence
staining ofHPB-MLT cell surface, approximately 1% ofall T cells
in PBL stain with mAb3A2 (data not shown) . AntiTCR0 frame-
work antibody, OR, was also made in this laboratory (13) . MAb
obtained from other sources includeLeu-4 (anti-CD3) (14), SPV
T3b (anti-CD3) (15), OKT4 (anti-CD4), OKT8" (anti-CD8) (16),
C305 (anti-V08) (17), aFl (antiTCR a chainframework) (T Cell
Sciences, Inc., Cambridge, MA), P3 (control) (18) and 187.1 (Rat
anti-mouse K chain) (19) .
Immunofluorescence andFlow Cytometry.
￿
Flow cytometric anal-
yses were performed using directly conjugated antibodies . Two-
color analyses on peripheral blood lymphocytes were carried out
as described previously usingaFACSCAN(Becton Dickinson and
Co ., Mountainview, CA) (20) . Viablecellswere analyzed by gating
on the propidium iodide negative lymphocytes.
Radiolabeling and Immunoprecipitation.
￿
Cell surface radiolabeling
ofHPB-MLT cells was performedby using Na15I and lactoperox-
idase as previously described (21) . Biosynthetic labeling ofTCR
chains from HPB-MLTwas carriedout as follows. Cellswere washed
and incubated at 5 x 106 cells/ml in methionine- and cysteine-
free RPMI-1640 containing 10% dialyzed FCS, 2mM glutamine
and 20 mM HEPES at 37°C in 5% COa atmosphere . After 30
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min, 0.5 mCi each of [3sS]-methionine and -cysteine were added
and incubation continued for 4 h . Cells were pelleted and lysed
in Tris-buffered saline (TBS, 50mM Tris pH 7.5, 150mM NaCl)
containing 1% Triton X-100, 1 mM PMSF and SmM iodoaceta-
mide . Cell lysateswere pre-cleared twice using normal rabbit serum
(NRS) and fixed S . aureus Cowan I (Pansorbin; Calbiochem-
Boehring Corp ., San Diego, CA). Specific immunoprecipitations
were carried out using amounts of ascites determined to be op-
timal; 6136 (0 .1 Al), 3A2 (0.4 wl), Len 4 (0.1 i4l), OR (0.25 p,l)
or ctF1(0.114) . In each case 150Al ofmAb 187.1 (rat anti-mouse
u) culture supernatant was added as a second antibody. After 60
min incubation at 4°C, 100pl of10% Protein-A sepharoseCL4B
(Pharmacia Fine Chemicals, Uppsala, Sweden) was added and in-
cubated further for 30 min. Immune complexes were washed in
0.1% Triton X-100, resolved by SDS-PAGE and analyzed by auto-
radiography as described (22) .
Derivation of6136' T Cell Clones.
￿
PBMC were stimulated in
vitrowith 50 ng/mlofmAb 6136 in RPMI-1640 containing 2mM
glutamine, 20mM HEPES, and 10% pooled human serum . Sec-
ondary stimulation was carried outusing autologous PBMC (4,000
rads) and 50 ng/ml of 6136 antibody. After 3 wk in culture, the
proportion of 6136+ cells in the CD3+ population rose from about
4% to 85%. Cells were cloned by plating at limiting dilutions in
media containing IIL2 and a panel of 6136+ and 6136 - T cell
clones was derived .
Southern Blot Hybridization .
￿
GenomicDNA was extractedfrom
T cellsby a standard technique (23) .DNA was digested withBam
HI restriction enzyme, size fractionated on 0.7% agarose gel and
transferred to Hybond-N nylon membranes (Amersham Corp.) .
DNA was cross-linked to the membranes byUVirradiation and
hybridized with 32P-labeled probes. The Va12 .1 probewas an Eco
RIAcc I (nucleotides -100 to +322) fragment of theTCRoe chain
cDNA clonepGA5 (24) . Va DNAfragment was radiolabeled with
[«-32p]-dGTP and -dCTP using random oligonucleotide primers
and Klenow. Likewise, PCRproducts generated using theV(O and
C/3-specific primers were size fractionated on 2% agarose gels, trans-
ferred to nylon filters, and hybridized with mixed 12P-labeled C/31-
(oligo #3CO) and C/32-specific (oligo #4CO) probes (see below) .
Statistical Analyses.
￿
To assess if the differences in expression of
Va12 .1 in the CD4+ and CD8' T cell subsets were significant,
two-sided Wilcoxon signed-ranked sum tests were used (25) .
hlymerase Chain Reaction.
￿
TotalRNAwas isolated from Ficoll-
purified mononuclear cells according to Chomczynski andSacchi
(26).cDNA was synthesized at 42°C in 50 pl reactions using0.5 Ncg
oligo (dT) primer, 4 to 8 hg totalRNA and10 U ofAMVreverse
transcriptase (Promega Corp., Madison, WI). After 1 h, the reac-
tion mixture was diluted to 100 pl, boiled and chilled, and cen-
trifuged to remove insoluble material. PCRwas performed in 25 pl
reactions containing 1 A1 ofcDNA (1/100), 1mm MgCl2, 10 mM
Tris pH 8.3, 1 mg/ml Gelatin, 5 pmole of each primer, 0.2 mM
ofeachdNTP and2UofTaq-Polymerase (Thermus aquaticusDNA
polymerase, Perkin-Elmer-Cetus Corp.) . Briefly,cDNA and primers
were pre-mixed with MgClz/Tris/Gelatin buffer and heated at
95°C for 7min . Other components were added, the reaction mix
was overlain with mineral oil, and 25 to 30 cycles of PCR were
carried out in a thermocycler (Perkin-Elmer-Cetus Corp .) at the
following settings : 0.7 min at 95°C for denaturation, 1 min at
56°C for annealing, and 1 min at 72°C for chain extension . To
ensure complete synthesis, the last cycle at 72°C was extended to
10 min .
Cloning in M13 and Sequencing
￿
Va111-specific (5' GGGG-
TCGACTTGCCAGCCTGTTGAGGGCAG 3') and Ca-specific
(5'GGGAAGCTTCTGGTACACGGCAGGGTCAGG 3') primerswere used to generate PCR products using cDNA from 6136+
T cell clones. Restriction sites in the PCR primers were used to
generate sticky ends for cloning. Appropriately sizedDNAprod-
ucts were then isolated from lowmelting point (LMP)agarose gels
(BRL, Gaithersburg, MD)and ligated toM13plasmids for cloning
and sequencing by the dideoxy chain termination method using
the modified T7 polymerase (Sequenase; United States Biochem-
ical Corp ., Cleveland, OH) (27) . The sequencing products were
resolved on polyacrylamide gels and autoradiography was carried
out according to standard methods .
Oligonucleodde Probes andPrimers.
￿
VO-specific PCR products
were generated using primers based on published sequences with
some modifications (28, 29) . The oligonucleotide sequences for the
VO-specific family members used in combination with the C/3
primers are listed below : V01-GGGGTCGACGCACAACAGT
TCCCTGACTTGCAC(+) ; V02-GGGGTCGACTCATCAACC-
ATGCAAGCCTGACCT(+); V#3-GGGGTCGACGTCTCTAG-
AGAGAAGAAGGAGCGC(+); V/34-GGGGTCGACACATATGA
GAGTGGATTTGTCATT(+); Vi35.1-G000TCGACATACTTC-
AGTGAGACACAGAGAAAC(+); V05.2/3-000GTCGACTTC-
CCTAACTATAGCTCTGAGCTG(+) ; V06.1/2/3-GGGGTCG-
ACAGGCCTGAGGGATCCGTCTC(+); V07-GGGGTCGACC-
CTGAATGCCCCAACAGCTCTC(+) ; Va8-GGGGTCGACAT
TTACTTTAACAACAACGTTCCG(+); V,B9-G000TCGACC-
CTAAATCTCCAGACAAAGCTCAC(+) ; V#10-000GTCGAC-
CTCCAAAAACTCATCCTGTACCTT(+ ); Vf11-000GTCGA-
CTCAACAGTCTCCAGAATAAGGACG(+) ; V#12-000GTCG-
ACAAAGGAGAAGTCTCAGAT(+); VQ13.1-GGGGTCGACC-
AAGGAGAAGTCCCCAATGGC(+); VS13.2-GGGGTCGACG-
GTGAGGGTACAACTGCCAAA(+) ; V014-000GTCGACGTC-
TCTCGAAAAGAGAAGAGGAAT(+) ; V,B15-GGGGTCGACAG
TGTCTCTCGACAGGCACAGGCT(+); V016-GGGGTCGAC-
AAAGAGTCTAAACAGGATGAGTCC(+) ; V,817-000GTCGA-
CCAGATAGTAAATGACTTTCAG(+) ; V018-GGGGTCGACG-
ATGAGTCAGGAATGCCAAAGGAA(+) ; VS19-GGGGTCGA-
CCAATGCCCCAAGAACGCACCCTGC(+); V020-GGGGT
CGACAGCTCTGAGGTGCCCCAGAATCTC(+) ; #1CO-GGG-
AAGCTTCTGATGGCTCAAACACAG(-); #2C#-GGGAAGC-
TTACACCAGTGTGGCCTTTTGGGTG(-) ; #3CSTCGGGT
GGGAACACGTTTTTC(-) ; #4COTCGGGTGGGAACACC-
TTGTTC(-).
The 5' sense strand primers V011, V#14, V#15, V018 andV#19
were used in combination with the 3' anti-sense primer #2CO, while
the rest ofthe V,8primerswere used in combination with the primer
#1Ca. This was to minimize PCR artifact (primer-dimer) forma-
tion due to possible 3`-end complementary bases shared between
sense and anti-sense primers . Synthetic oligonucleotides were ra-
diolabeled at the 5' termini with [y-'2P] using the enzyme bacte-
riophage T4 polynucleotide kinase. Allofthe PCRproducts were
size fractionated, transferred and hybridized with internal region
CO probes, #3C,8and#4CO. VJ3specificPCRproducts were visual-
ized by autoradiography and radioactivitywas counted directly by
using a blot analyzer (Betascope 603; Betagen Corp.) .
Results
MAb6136 is Specficfor 7CR Va12.1.
￿
To facilitate direct
examination of the TCR repertoire in man, a murine mAb
directed against a Va111 determinant was established (see
MaterialsandMethods) .MAb6136bound specifically to the
surface ofHPB-MLT cells (the immunizing cell line) and to
approximately2% to 4% ofperipheral T cells from normal
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HPB-MLT JURKAT PBL
P3
(control)
6D6
(anti-Va 12 .1)
C305
(anti -VP8)
SPV-T3b
(anti -CD3)
Figure 1 .
￿
Cell surface reactivity ofmAb 6136 . MAb 6136 stained HPB-
MLT cells and a small subpopulation (2-5%) of peripheral blood lympho-
cytes but not theJurkat T leukemia cell line. Staining ofJurkat cells and
PBLwith the V08-specific mAb C305 is shown for comparison (17) . lso-
type matchedmAbP3 was used as a negative control and mAbT3b (anti-
CD3) was used as positive control . MAb 6136 was generated against the
a(3 TCRcomplex isolated from HPB-MLT as described in Materials and
Methods. Cell number scale is linear, fluorescence intensity scale is log.
individuals (Fig. 1) . Forcomparison,mAb C305, specific for
V08encodedTCR products, also reactedwith afew percent
of peripheral blood T cells and the Jurkat cell line (which
expressesVS8) but not withHPB-MLT cells (which express
Va111 andV05.3) (Fig. 1) .
To determine the nature of the molecule recognized by
mAb 6136, immunoprecipitations were performed on 1251_
labeled HPB-MLT cell lysates followed by SDS-PAGE and
autoradiography. ThemAb immunoprecipitated theTCRaft
heterodimer (85 W) under nonreducing conditions (Fig . 2
A, lane 4) . This 85 kD heterodimer resolved into two spe-
cies with Mr 46 kD (TCRct) and 39 kD (TCR,6) under
reducing conditions (Fig. 2A, lane 8) . Forcomparison, similar
radiolabeled species were visualized after immunoprecipita-
tions with TCR,B-specific mAbOF1 and CD3E-specificmAb
Leu 4 (Fig. 2A) . In both antiTCRandanti-CD3 immuno-
precipitations, a variable degree of coimmunoprecipitation
of the other components was noted .
To delineate theTCR chain specificity ofmAb 6136, im-
munoprecipitations were carried out on HPB-MET cell ly-
sates metabolically labeled with 35[S]-methionine and -cys-
teine. Under these conditions adetectable fraction ofthe newly
synthesizeda and aTCR chains were still unpaired, such
that mAb 6136 immunoprecipitated both a free a chain
(migrating as a sharpband at 43W), andtheaio-heterodimers
as fully glycosylated (80-85 kD) and partially glycosylated
(70-75 W) structures (Fig . 2B, lane 3) basedon sizes reported
earlier (30) . Immunoprecipitation with theanti-TCRafi-ame-
work antibody, ciF1, confirmed that the 43 kD species was
the unpaired TCRa chain subunit (Fig . 2 B, lane 4) . TheFigure 2 .
￿
Immunochemical characterization ofmAb 6136 reactivity. (A) Immunoprecipitations of the a/3 TCR complex from cell surface 1251 ra-
diolabeled HPB-MLT cells were resolved by SDS-PAGE and analyzed by autoradiography. Antibodies were P3 (negative control), Leu4 (anti-C133),
On (anti-(3 framework) and 6136 . Under nonreducing (NR) conditions (lanes 1-4), the a(3 TCR complex was resolved as a 85 kD species by direct
immunoprecipitation with mAbsSM ,and 6D6 or by co-immunoprecipitation with anti-CD3 mAb Leu 4 . Under reducing (R) conditions (lanes S-8),
the TCR a and Q subunits were visualized as 46kD and 39 kD species, respectively. Note the CD3 subunits at 20-30M (B) MAb 6136 recognized
a determinant present on the a chain of the HPB-MLTTCR complex . HPB-MLT cells were metabolically labeled with 35(S)-methionine and -cysteine
for 4 h and solubilized in 1% Triton X-100. Immunoprecipitations were carried out with the indicated antibodies, and resolved by SDS-PAGE under
nonreducing (NR) conditions and visualized by fluorography. MAbs OR (TCR /3 framework) and 3A2 (antiVO5) immunoprecipitated the unpaired
(3 chain (lanes 2 and 3, respectively) . In contrast, otF1(anti-framework) and 6136 antibodies (lanes 4 and S, respectively) immunoprecipitated the unpaired
a chain from HPB-MLT cell lysates. WhilemAb ctP1 immunoprecipitated all of the glycosylated a chain species identified in HPB-MLT (13), mAb
6136 immunoprecipitated only one of these species . Note that mAb 6136 also recognized the TCR a/3 heterodimer as fully (80-85 kD) and partially
(70-75 kD) glycosylated complexes (see text) .
other radiolabelled species (41-44 kD) in the c&l precipita-
tion presumably corresponded to differentially glycosylated
a chain species, as reported previously (13) . By comparison,
other mAbs .that we generated including the anti-TCR (3
framework antibody, OR (lane 2), and antibody against the
V6 product ofHPB-MLT (3A2) (lane 3) both immunopre-
cipitated the unpaired /3-chain (38 kD) but not any of the
free a chain species . Thus, mAb 6136 reacted with a deter-
minant expressed on the TCRa chain .
To examine whether this determinant was encoded byVa,
jot or a combination of both gene segments, 6136+ T cell
clones derived from healthy individuals were analyzed .
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Southern blot analysis using the Va12.1-specific (pGA5) probe
showed this Va gene to be rearranged in all the 6136+ T
cell clones and the HPB-MLT leukemia cell line (Fig . 3 A) .
The fact that the rearranged fragments were ofdifferent sizes
in each cell line indicated that theVa12A gene segment which
is part of a Va family having only one member (24, 31),
might be rearranging to several different Jot gene segments.
This suggested that mAb 6136 recognized aVa rather than
aJot gene segment encoded determinant . Similarly, Northern
blot analysis revealed expression of Va12.1 transcripts in
6136+ T cell clones (data not shown) . These conclusions
were confirmed by determining the nucleic acid sequencesFigure 3 .
￿
Va12 .1 gene segment encodes the determinant recognized
by mAb 6D6 . (A) 6D6+ T cells contained different Va12 .1 gene rear-
rangements. DNA from 6D6+ T cell clones HD5.A (lane 4) andHD5.B
(lane 5), T cell leukemia cell line HPB-MLT (lane 3), and the 6D6 - T
cell clone 3A2.D were digested with Bam HI and analyzed by Southern
hybridization using a Va12.1-specific probe. Germline configuration (GL)
for Va1I1 gene was seen as a 6 .3 Kb fragment in the B cell line, SB
(lane 1) . While both Va12 .1 alleles in 3A2.DT cell clone were deleted,
DNA fromHD5.A, HD5.B andHPB-MLT showed distinct Va12.1 rear-
rangements (R). (B) Partial nucleic acid sequences ofHD5.A,HD5.B and
HPB-MLT (24) TCRa chain transcripts showed in-frame Va1Il gene
rearrangements with different Ja gene segments (JA30, Q, and A) . cDNA
sequences for HD5.A and HD5.B TCR a chain transcripts were gener-
ated byPCR using Va12 .1- and Ca-specific primers as described inMaterials
and Methods .
of the ot chain junctional regions of 6D6+ T cell clones
HD5.A and HD5.B, and compared with the reported
HPB.MLT sequence (24) . Each of the three 6D6 + T cell
lines contained in-frame Vot12.1 rearrangements to distinct
Jot gene segments (Fig. 3 B) . These results demonstrated that
mAb6D6 specifically recognized the product encoded by the
human V(r12.1 gene segment .
Increased Frequency of Va12.1 + T Cells in the CD8`
Subset. Expression of the Vacll1 gene segment in the total
PBL varied from 1.4% to 4.5% of the CD3 + lymphocytes
= 3.5%) . When Vcx12.1 gene expression was analyzed
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among the CD4' or CD8+ T cells by two-color staining
(an example is shown in Fig. 4 A), it was evident that most
individuals had a non-random distribution of this gene seg-
ment among the two subsets (Fig . 4 B) . Analysis of the two
phenotypic subsets separately showed that approximately 80%
of individuals had a 1.5- 3-fold higher frequency ofVa12.1
among CD8+ T cells (x = 4.2% ; range 1.4% to 7.2%)
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Figure 4 .
￿
Two-color immunofluorescence analysis of 6D6 expression
on CD4+ and CD8+ T cells . (A) PBMC from adult and newborn were
stained with anti-CD4 (OKT4) or anti-CD8 (OKT8) (green fluorescence)
and anti-Va1Il (6D6) (red fluorescence) mAbs as described in Materials
and Methods. Lymphocytes were gated on the basis of forward and side
scatter profiles (not shown) and analyzed for fluorescence intensity in log
scale . Dot plots were divided into quadrants to represent unstained cells
(lower left, quadrant 3), cells stained with FITC alone (lower right, quad-
rant 4), cells stained with PE alone (upper left, quadrant 1), and cells that
double stained with FITC and PE (upperright, quadrant 2) . (B) Thea12 .1
expression in CD4+ and CD8'' T cells from adult and newborn PBL was
determined using data derived for individual blood samples stained as
inA . The expression of Va1Il in the CD4' and CD8+ subsets for each
individual are connected by a line. The following formula was used to
calculate the percentage value for 6D6 expression in CD4+ or CD8+
T cells: % 6D6+/CD4+ (or CD8+) cells - (6D6+ cells co-stained with
CD4 (or CD8) in PBMC (2nd quadrant)/% T cells that were CD4+ (or
CD8+)) x 100.compared to CD4+ T cells (- x = 2.7% ; range 1.4% to
3.6%) (p = 0.0044) (Fig. 4 B, Adult) . Only 20% ofindivid-
uals used W12 .1 at similar frequency among CD4+ and
CD8+ T cells. This result indicated that T cell receptor Va
gene usage in man is nonrandom .
This differential usage could have resulted either from de-
velopmental influences or from peripheral expansion as a con-
sequence of foreign antigenic challenges. To distinguish these
two possibilities, Va12.1 expression was examined in new-
born peripheral (umbilical cord) blood samples. Similar to
the results seen in adult peripheral blood, significantly higher
percentages of Va1I1 expression were seen in the CD8+
T cells of 10 newborns (p = 0.002) (Fig . 4 B, Newborn) .
These data in the peripheral blood of newborns suggested
the skewing was not likely to be the result of peripheral anti-
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genic challenges and pointed instead to a developmental mech-
anism, possibly thymic selection .
Analysis of V,8 Usage in Va12.1 + T Cells by Quantitative
PCR . The preferential VcdI1 expression on CD8+ T
cells was unexpected because essentially all known develop-
mentally determined differences in TCR V gene usage are
based on TCR V(3 expression and the presumed interaction
of this gene segment with self-MHC or self-MHC antigen/su-
perantigen complexes (32) . Therefore, it became important
to examine TCR VJi usage in cells expressing the VcdI1
gene product . For this analysis, we used the PCR with VO-
specific oligonucleotides known to detect up to 90% of all
knownhuman Vii genes. Such quantitative PCR techniques
may not determine the precise percentage ofT cells bearing
the respective V genes (in-frame and out of frame sequences
Figure 5 . V/3 gene usage in
Vot12 .1* T cells analyzed by quantita-
tive PCR-hybridization . cDNA from
CD4" and CD8+ T cells expressing
the Va12 .1 (6D6+) were used to
generatePCR products using V/3 and
C(3-specific primers, size fractionated,
and hybridizedwith an internalconstant
region (C/3) 32P-labeled probe (see
Materials and Methods) . (A) An ex-
ample of a southern blot analysis ofthe
specific expression ofV01, V02, V03,
V04, V05 .1, V05.2/3, V06.1/2/3,
V07, V08, V,69, V010, V011, Va12,
V013 .1, Vp13 .2, V014, V015, Vp16,
V017, V018, V019, and V020 gene
segments in the 6D6-selected
(Vu12.1*) CD4+ and CD8+ T cell
subsets as represented in autoradio-
graphic form. (B) Relative percentage
of expression of each Vl gene. The
amount of VAspecific expression in
CD4+ and CD8+ cells was quanti-
tated by directly measuring the radio-
activity hybridized to each VO-specific
PCR products by a blot analyzer (Be-
tascope 603 ; Betagen Corporation,
Waltham, MA) . The data are presented
as percentages in a bar graph. TheY-axis
represents percent VS expression in
CD4+ (solid bars) and CD8+ (open
bars) in Vca12.1+ (6D6-selected; upper
panel) and total (6D6-unselected; lower
panel)T cells . The percent V,Q expres-
sion for each sample was calculated
using the following formula : %VS =
Hybridization to VOspecificPCRprod-
ucts in cpm/Sum of all VOspecific
hybridizations in cpm) x 100 .are not distinguished for example), but such approaches are
known to be useful in approximating relative V gene usage
(29) . Moreover, our own efforts to validate the procedure
by mixingmRNA fromT cell lines ofknownV gene usage
revealed the expected proportions byPCR, at least for a sample
of 3 V(3 genes analyzed (data not shown) . In Va12.1+ (6136
selected) T cells, quantitative hybridization of VOspecificPCR
products revealed that the majority of the V/3 genes were
shared equally between the CD4+ and CD8+ subsets (Fig .
5 A and 5 B, upper panel) . No single V/3 gene dominated
in its association with Va12.1 . Importantly, the overall
similarity in Va usage on Va12 .1 bearing CD4+ andCD8+
T cells suggested that skewed V(3 usage was not responsible
for the increased level of Va111 expression on CD8+ T
cells . In addition, most of the V# genes that were studied
in the 6136 selected (Va111 +) T cells were detected in
similar amounts in CD4+ and CD8+ T cell subsets that had
not been selected for Voa111 expression (Fig. 5 B, 6136 un-
selected; lower panel) . Thus V02, V07, V08 and V(313 which
were the most prominently used VO genes in the Vcd1l
selected T cells were also prominently used in C134' and
CD8+ T cells not selected for Vcd1l expression (Fig. 5 B,
compare patterns in upper and lower panels) . Moreover, the
least frequently used Vss (V05, V)310, Va11, V316, V017,
V018 and V#19) were also similar.
Some differences in VO expression among the subgroups
were noted. For example, Vf7 andVa13.1 which accounted
for 11% and 10.4% of the Vii gene segments in the
Va12.1 +/CD8+ subgroup were used at relatively lower
levels in the Va12.1+/CD4+ subset where they made up
7.5% and 5.3%, respectively (Fig. 5 B, upper panel) . These
usage levels together accounted for about a 9% difference
between the two subsets . In fact, the sum of all differences
in Vii frequency between the Vod2.1+/CD8+ and
Va12.1 +/CD4 + T cells was only 16% . This total difference
inV# usage was substantially less than the 60% that would
have been required if skewed Vfl usage was to account for
the 2.5-fold increase in Vcd1l expression in this individ-
ual's CD8+ T cells .
While the above analysis examined V(3 expression on
Vcd1l selected CD4+ versus CD8+ T cells, we also com-
pared VO expression in Vcd1l selected and unselected T cell
populations, we noted some evidence for preferential V(3 usage.
For instance, in the CD4 + subset, V(615 was present on ap-
proximately 11% of the Va12.1+ T cells compared with
only approximately3% oftheT cell population not selected
forVa12.1 expression. In contrast, V013.1 was less frequently
used in Va111+ T cells (Fig . 5 B, compare upper and lower
panels) . Nevertheless, even in these few examples whereVa
differences were seen between Vcd1l selected and unselected
T cell populations, the differences were apparent to a nearly
equal degree in both the CD4 + and CD8+ subsets, and
therefore would seem not to be a likely explanation for the
increased Va12.1 expression on CD8+ T cells.
It is important to note that all of the V(3s tested are capable
of association with Va12.1 and that no major Va product
dominated in association with the Vcd1l gene product . A
similar analysis ofVO usage in newborn umbilical cord blood
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also showed no dominant VO expression in association with
Va12.1 and no significant difference in V# usage by the
CD4+ and CD8+ subsets (data not shown). Thus, one
cannot readily account for the significantly higher expres-
sion of Vcd1l on CD8+ T cells based on VO skewing.
Discussion
Ever since early functional studies pointed to the require-
ment for self-restriction in T cell recognition of foreign an-
tigens, immunologists have tried to understand thisphenom-
enon in molecular terms (33) . The binding ofantigen peptides
toMHC molecules has provided a molecular explanation for
corecognition of Ag/MHC by the TCR (34-37), but the
way in which different components of the TCR contribute
to this Ag/MHC recognition has not been fully delineated .
TCR gene sequences and hypothetical modeling based on
immunoglobulin molecules suggest that the TCRV regions
(especially those regions corresponding to CDR1 and CDR2)
contact theMHC molecule, while the highly diverseV(D)J
junctional region (corresponding to CDR3) contacts anti-
genic peptides bound to theMHC molecule (3, 10) . If these
assumptions are correct, it should bepossible to correlateTCR
germline gene segment usage with Ag/MHC recognition .
In fact, several studies in mice have provided direct correla-
tions between TCR V(3 gene segment usage and recogni-
tion of specific class II MHC/Ag complexes, mostly in as-
sociation with the Mls antigens (38-41) . However, the
molecular basis ofself-MHC recognition by the TCR is likely
to be more complex than our current understanding which
emphasizes only TCR VO gene products . The Va encoded
regions also are likely to be important in Ag/MHC recogni-
tion as predicted by the molecular model .
With regard to the role ofthe TCR a chain, a few studies
have correlatedVa usage with foreign peptide or hapten rec-
ognition (42-45) . Surprisingly, no molecular evidence has
demonstrated a role for theVa gene segment in the recogni-
tion ofMHC orAg/MHC complex . This is in part because
few Va-specific mAb have been available (46, 47) . Moreover
in man, the greater number of germline gene segments, the
more polymorphicMHC, and the inability to control genetic
variation account for the fact that data measuring the actual
TCR a or /3 repertoire and its relation to MHC-linked rec-
ognition and selection are currently very limited .
This study analyzes the cell surface expression ofthe human
TCR Vcd1l gene product on CD4 + versus CD8+ T cells.
Using a Va specific mAb, expression of the Va12.1 gene
segment was found to be significantly higher on CD8+ T
cells in many of the individuals examined . Since CD8+ T
cells in the periphery are class I MHC-restricted, the pre-
dominant expression ofVcd1l on CD8+ T cells makes it
likely that the product encoded by this gene segment is used
preferentially on class I MHC-restricted T cells inman . Based
on our current understanding ofMHC molecule expression,
it is likely that the class I MHC molecule is expressed on
the cell surface only in association with foreign or self-peptides
(36) . Therefore, Vcd1l may be interacting directly with
MHC and/or with a peptide bound to it . While a precisedefinition of what the Va is interacting with in this case
is not known, the data are consistent with the likelihood that
Va12.1 is playing a role on CD8' T cells in recognition of
class I MHC/Ag complex in vivo.
The increased expression of Va12.1 in CD8+ T cells was
apparent also in newborn samples, where environmental
influences on theTCR repertoire via antigenic challenge would
not yet have occurred . Thus it seems likely that the biased
Va12.1 usage results from developmental factors, rather than
environmental ones. At present,we cannot distinguish thymic
from extrathymic developmental influences, nor can we im-
plicate a particular mechanism ofthymic selection. In general
(48), although not in every case (49), it has been suggested
that negative selection of self-reactive thymocytes results in
clonal deletion at the double positive (CD4+8+) stage of
differentiation, resulting in deletion of the progenitors ofboth
CD4+ and CD8+ mature T cells (50) . In contrast, positive
selection has been suggested to result in the unequal distri-
bution of the TCR repertoire between the CD4+ or CD8+
T cell subsets (7, 10, 51) . However, the actual mechanisms
involved in thymocyte maturation are not well understood
and selection may influence the T cell receptor repertoire at
several intermediate stages during differentiation (52) . We
find it attractive to hypothesize that positive selection in the
thymus plays a role in the preferential Vca12.1 expression in
the CD8+ T cells by expanding a subset ofMHC class I-
restricted T cell precursors bearing Va12.1 . Nevertheless, the
data presented do not resolve the mechanism operating and
further studies are needed to understand more fully the basis
of biased Va12 expression .
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